NZ517802A - Surface cross-linked particles suitable for controlled delivery in pharmaceutical use - Google Patents

Surface cross-linked particles suitable for controlled delivery in pharmaceutical use

Info

Publication number
NZ517802A
NZ517802A NZ517802A NZ51780202A NZ517802A NZ 517802 A NZ517802 A NZ 517802A NZ 517802 A NZ517802 A NZ 517802A NZ 51780202 A NZ51780202 A NZ 51780202A NZ 517802 A NZ517802 A NZ 517802A
Authority
NZ
New Zealand
Prior art keywords
acid
dihydrazide
group
cross
spacer
Prior art date
Application number
NZ517802A
Inventor
Gregory Russell-Jones
Scott Mathew Starling
Original Assignee
Biotech Australia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO8880A external-priority patent/AUPO888097A0/en
Application filed by Biotech Australia filed Critical Biotech Australia
Publication of NZ517802A publication Critical patent/NZ517802A/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cross-linked particles that are useful for delivery of pharmaceutical agents are disclosed, wherein these cross- linked particles comprise at least one polymeric compound and a spacer compound, where the polymeric compound and the spacer each comprise reactive carboxyl, hydrazidyl, amino and/or thiol groups. The particles are cross-linked via covalent linkage of the reactive groups on the polymer and spacer respectively. Compositions comprising pharmaceutical agents contained within the particles are disclosed. Methods for preparing the particles, for encapsulating pharmaceutical agents within the particles, and for using the particles for controlled release of the pharmaceutical agent within the patient also are disclosed.

Description

Patent Form No. 5 1 78 0 2 DIVISIONAL OUT OF APPLICATION NO. 503579 ANTE-DATING REQUESTED TO 27 MARCH 2000 PATENTS ACT 1953 COMPLETE SPECIFICATION Cross-Linked Particles We, Biotech Australia Pty Ltd (client), a company incorporated in Australia, of 28 Barcoo Street, Roseville, New South Wales, 2207. hereby declare the invention, for which We pray that a patent may be granted to us, and the method by which it is to be performed to be particularly described in and by the following statement: 1 (the next page is numbered la) intellectual property office of n.z. 1 4 MAR 2002 received CROSS-LINKED PARTICLES Field of the Invention The present invention relates to cross-linked particles useful for 10 pharmaceutical delivery. In particular, the invention relates to improved methods of stabilizing such particles and controlling uptake and pharmaceutical agent release within a vertebrate host.
Background of the Invention 15 The effective delivery of a pharmaceutical agent to an active site and achieving an acceptable rate of release of pharmaceutical agents are enduring problems in developing and improving pharmaceutical therapies. In particular, it is well recognized that the gastro-intestinal tract of vertebrate animals provides a number of physical and chemical barriers against the successful 20 administration of therapeutic agents. For example a therapeutic agent must be able to withstand the attack of endogenous enzymes, gastric acidity and intestinal alkalinity without losing activity, and then still penetrate across the gastrointestinal mucosa, into the blood stream and to the site where activity is required. Moreover, all of this must take place at an appropriate rate to ensure 25 the correct therapeutic dosage is delivered.
In the past, many approaches have been adopted to attempt to solve these problems. For example, administration of a particularly high dose of active agent can be effective in ensuring that at least some of the agent reaches the 30 desired active site without degradation. This approach to administration of enteric agents is clearly problematic and not economical. In some instances it can be appropriate for simple mechanical carriers such as pressed tablets or enteric coatings to be provided in order to improve enteric tolerance of the agent concerned, and to regulate the rate of drug release. There has also been 35 considerable research recently to develop liposomes or lipid microbubbles that can be used to encapsulate active agents. These approaches have not been successful in all circumstances.
Micro and nanoparticles which can encapsulate pharmaceutical agents in 40 order to provide protection and regulate their rate of release were described in United States Patent No. 5,352,461. This patent relates to the self-assembling - 1A- PCT/1B98/01464 particle drug delivery systems formed from 2,5-diketo-3,6-di(4-succinylaminobutyl)piperazine, which are claimed to be pH sensitive so that they therefore disassemble and release the entrapped pharmaceutical agent, at high pH. Other particles which are suggested as being able to encapsulate 5 agents such as insulin and heparin and protect these molecules from gastric acidity and stomach enzymes, and to release the agents into the bloodstream, were proposed in International Patent Publication No. WO 88/01213. Self-assembling pH titratable particulate systems, based upon the self-assembling properties of bis-amide dicarboxylic acids are described in the work of 10 Bergeron et al., J. Amer. Chem. Soc. 1995, 117, 6658-6665. These particles also share the properties of stability at low pH and instability as pH increases.
International Patent Publication No. WO 96/29991 describes the formation of self-assembling particles that are based upon polyaminoacids, more 15 particularly polyleucine-glutamate. These particles which are prepared from natural amino acids have the property of controlled particle size and are stable over a wide pH range.
Particles for entrapment of pharmaceutical agents, and particularly 20 peptides or proteins, can also be formed by polyelectrolyte complexation of various anionic polymers with cationic polymers. Anionic polymers may include natural substances such as sodium alginate, carboxymethyl cellulose, guaran, polyglutamic acid and their derivatives, amongst others. Examples of cationic polymers include polylysine and gelatin. Other polycations and 25 polyanions are described in detail within European Patent No. 671169, United States Patent No. 4,835,248 and United States Patent No. 5,041,291, which are incorporate herein by reference in their entirety.
Unfortunately, there are limitations to the effectiveness of particles for 30 pharmaceutical delivery according to the prior art, as it has been found in many cases that these particles rapidly release the entrapped pharmaceutical agent upon parenteral or enteral administration. As a result, efforts have been made to develop stabilised microparticles by the use of glutaraldehyde cross-linking. This method of cross-linking however suffers from the disadvantage that it can 35 result in the modification of the entrapped pharmaceutical agent, which is clearly undesirable. A further disadvantage is that such cross-linking is optimally performed under alkaline conditions, the same conditions under which many of these pH-sensitive particles will rapidly release the entrapped pharmaceutical agents.
It is apparent, therefore, that practical methods of particle stabilisation that are suitable for use with pH-sensitive particles and which can be performed with little or no risk of modification of the entrapped pharmaceutical agent are greatly to be desired. In particular, methods that can be used for delivery of 5 pharmaceutical agents are highly desirable.
Summary of the Invention It is therefore an object of the present invention to provide practical methods of particle stabilization which reduce or eliminate modification of an entrapped pharmaceutical agent.
It is a further object of the present invention to provide methods for 15 delivering pharmaceutical agents that reduce or eliminate modification of the pharmaceutical agent.
In accomplishing the foregoing objects, there have been provided, in accordance with one aspect of the present invention, cross-linked particles which 20 can be formulated using the following components: a) one or more polymers capable of forming a particle, each comprising reactive carboxyl, hydrazidyl, amino and/or thiol groups; and b) a spacer comprising two or more reactive carboxyl, hydrazidyl, amino and/or thiol groups groups; wherein cross-linking is achieved by carbodiimide linkage between the carboxyl group and the hydrazidyl, amino and/or thiol groups of the polymer(s) and the spacer.
According to another embodiment of the present invention there is 30 provided a composition comprising a pharmaceutical agent entrapped within a cross-linked particle, wherein the cross-linked particle comprises: a) one or more polymers capable of forming a particle, each comprising reactive carboxyl, hydrazidyl, amino and/or thiol groups groups; and b) a spacer comprising two or more reactive carboxyl, hydrazidyl, amino and/or thiol groups groups; and wherein cross-linking is achieved in the presence of the pharmaceutical agent and is catalyzed by carbodiimide linkage between the carboxyl group and the, hydrazidyl, amino and/or thiol groups of the polymer(s) and the spacer.
According to a further embodiment of the present invention there is provided a method of producing a cross-linked particle which comprises reacting, under appropriate conditions: a) one or more polymers capable of forming a particle, each 5 comprising reactive carboxyl, hydrazidyl, amino and/or thiol groups; and b) a spacer comprising two or more reactive carboxyl, hydrazidyl, amino and/or thiol groups; and; wherein cross-linking is achieved by carbodiimide linkage between the 10 carboxyl group and the hydrazidyl, amino and/or thiol groups of the polymer/s and the spacer.
According to another embodiment of the present invention there is provided a method of producing a composition containing one or more IS pharmaceutical agents, comprising reacting a cross-linked particle with one or more pharmaceutical agents, wherein the panicle comprises a) one or more polymers capable of forming a particle, each comprising reactive carboxyl, hydrazidyl, amino and/or thiol groups; b) a spacer comprising two or more reactive carboxyl, hydrazidyl, amino 20 and/or thiol groups; and wherein cross-linking is achieved by carbodiimide linkage between the carboxyl group and the hydrazidyl, amino and/or thiol groups of the polymer/s and the spacer.
According to still another embodiment of the present invention there is provided a method of controlled pharmaceutical agent release in a patient, comprising administering to said patient an effective amount of a composition comprising a pharmaceutical agent entrapped within a cross-linked particle, wherein said particle comprises: a) one or more polymers capable of forming an encapsulating particle, each comprising reactive carboxyl, hydrazidyl, amino and/or thiol groups; and b) a spacer comprising two or more reactive carboxyl, hydrazidyl, amino and/or thiol groups.
In these embodiments, the spacer preferably has the formula: NH2NHCO-R-CONHNH2t where -R- is a direct bond, or R is a straight, branched chain or cyclic alkyl, alkenyl, alkynyl or aryl group, and where the alkyl, alkenyl, or alkynyl group contains up to 10 carbon atoms. The 40 spacer also may be selected from the group consisting of: hydrazine, oxalic dihydrazide, malonic dihydrazide, succinic dihydrazide, glutaric dihydrazide, adipic dihydrazide, maleic dihydrazide, fumaric dihydrazide or butadienoic dihydrazide, glutamic dihydrazide, aspartic dihydrazide, malic dihydrazide, tartaric dihydrazide, terephthalic dihydrazide, isophthalic dihydrazide, and 5 phthalic dihydrazide.
In further embodiments, the spacer may be selected from the group consisting of malonic acid, maleic acid, malic acid, citric acid, glutamic acid, aspartic acid, succinic acid, adipic acid, glutaric acid, dimethylglutaric acid, 10 oxalic acid, fumaric acid, phthalic acid, tartaric acid, isophthalic acid, and terephthalic acid and the branched alkyl derivatives thereof, wherein the alkyl group of said alkyl derivatives contains up to 10 carbon acorns- In still further embodiments, the spacer comprises at least one reactive 15 carboxyl group and at least one reactive hydrazidyl group. The spacer also may comprise at least one biodegradable linkage. The biodegradable linkage may be an ester linkage, for example where the spacer is a 2-aminoethyl ester of an amino acid. In a preferred embodiment, the spacer is a 2-aminoethyl ester of glycine or phenylalanine, or a disuccinimidyl derivative thereof. In a preferred 20 embodiment,the disuccinimidyl derivatives of the 2-aniinoethyi esters of glycine and phenylalanine are selected from the group consisting of N,N'-disuccinimidyI-(2-amino-2-benzyl-ethanoate), N,N'-dissuccinimidyl-2-amino-ethyl-ethanoate, and ethylene glycoIbis[succinimidylsuccinate] The cross-linked particle may be covalently bound to a targeting compound. In other embodiments, the pharmaceutical agent is selected from the group consisting of peptide and protein pharmaceuticals, DNA, RNA, antibodies, vaccines, imaging agents, hormones, polysaccharides, antibiotics, anticoagulants, immunomodulating agents, cytotoxic agents, steroids, 30 decongestants, anesthetics and sedatives. In preferred embodiments, the pharmaceutical agent is selected from the group consisting of calcitonin, erythropoietin, thrombopoietin, granulocyte colony stimulating factor, stem cell factor, LHRH analogs, somatostatin, insulin, interferons and plasminogen activator inhibitors.
Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since intellectual property -5- I OFFICE OF N.Z.
SEP 2003 WO 99/11703 PCT/1B98/01464 various changes and modifications within the spirit and scope of the invenaon will become apparent to those skilled in the art from this detailed description. s Brief Description of the Figures Figure 1 shows a plot of the change in serum glucose levels in male Wistar rats following intravenous administration of insulin and insulin entrapped within a cross-linked particle formed from gelatin and carboxymethyl cellulose (CMC). The plot shows percentage serum glucose concentration (relative to 10 serum glucose concentration at time 0), versus time. Blood analysis was conducted at 0, 1, 2, 3, 4, 5 and 6 hours post-administration. The rats are administered either highly cross-linked particles, moderately cross-linked particles, particles with a low degree of cross-linking or an insulin control. Each of the rats was administered either 100 |ig of insulin or a preparation of IS particles containing 100 \ig of insulin.
Figure 2 shows a plot of the change in serum glucose levels of male Wistar rats following intravenous administration of insulin and of insulin entrapped within a cross-linked particle formed from gelatin and polyglutamic 20 acid [Gel/P-GIu] or gelatin and adipylhydrazidyl [Gel/AH-P-Glu]. The plot shows percentage serum glucose concentration (relative to serum glucose concentration at time 0), against time. Blood analysis was conducted at 0, 1, 2, 3, 4, 5 and 6 hours post-administration. Each of the rats was administered either 100 tig of insulin or a preparation of particles containing 100 fig of 25 insulin.
Figure 3 shows the effect on the glucose levels in rats upon administration of insulin-containing particles. Cross-linking with EDAC and AH greatly reduced the rate of release of insulin from the particles.
Figure 4 shows the effect of increasing quantities of esterase-cleavable cross-linker on the in vivo rate of release of insulin from AH-CMC nanoparticles.
Figure 5 shows the reduction in serum glucose level in rats following oral administration of vitamin B12-conjugated insulin-containing IBCA nanoparticles.
PCT/1B98/01464 Detailed Description of the Invention Cross-linked particles are provided that are useful for delivering pharmaceutical agents that otherwise would experience a loss of efficacy as a result of instability, inadequate uptake, or an inappropriate rate of release. In s particular, the pharmaceutical agents comprehended by the present invention include peptide and protein pharmaceuticals which are subject to proteolytic degradation or are otherwise unstable in the stomach and small intestine.
In general, the preferred method for administration of therapeutic agents 10 is via an enteric, and particularly oral, route. This provides ease of administration and an associated high level of patient compliance. However, many therapeutic agents currently cannot be effectively delivered via an oral route. Examples of such agents include peptide and protein pharmaceuticals include calcitonin, erythropoietin, thrombopoietin, granulocyte colony is stimulating factor, stem cell factor, LHRH analogs, somatostatin, insulin, interferons, plasminogen activator inhibitors, recombinant antibodies and monoclonal antibodies. In the context of the present invention, the term "pharmaceutical agent" is not in any way limited to peptide and protein pharmaceuticals, but includes any therapeutic, prophylactic or diagnostic agent 20 whose delivery may be aided by using the cross-linked particles according to the present invention. For example, delivery of species of DNA and RNA (sense or antisense), antibodies, vaccines as well as more traditional chemotherapeutic agents is contemplated. Thus, the term "pharmaceutical agent" is to be understood as encompassing simple organic or inorganic compounds, nutritional 25 agents and imaging agents such as metals, radioactive isotopes, radio-opaque or radiolucent agents. Examples of "traditional" chemotherapeutic agents include hormones, polysaccharides, such as heparin, antibiotics, anti-inflammatory compounds, antivirals, vasoactiv- and neuroactive agents, anticoagulants, immunomodulating agents, cytotoxic agents, steroids, decongestants, 30 anaesthetics, sedatives and any other agents required to be delivered to a patient for therapeutic, prophylactic or diagnostic purposes. This list of classes of pharmaceutical agents is not intended to be exhaustive.
In addition, the pharmaceutical agents according to the invention can 35 occur in various forms, for example as charged or uncharged molecules, as components of molecular complexes, as salts, amines, ethers, esters, or amides, or as other derivatives or pro-drugs of the agents concerned.
The present invention is not limited to enteric delivery of pharmaceutical 40 agents. For example, parenteral delivery of pharmaceutical agents can also benefit from the present invention, such as when a pharmaceutical agent must penetrate barriers (other than the gastrointestinal mucosa) within the body in order to reach the target organ or target site. The blood-brain barrier is one example of such a barrier. In addition, a pharmaceutical agent may be 5 delivered to, and retained at, a particular active site.
In the context of the present invention, the term "cross-linked" indicates that covalent chemical linkages are introduced within and/or between the polymers that comprise the particle. This cross-linking increases the stability of 10 the particle, thereby providing better protection to the entrapped pharmaceutical agent, as well as improving the level of control that can be exerted over the timing and rate of pharmaceutical agent release. applied to any type of particle that either is already known, or that may be devised in the future, provided that the polymer components of the particle either comprise, or can be modified to comprise, reactive carboxyl, hydrazidyl, amino and/or thiol groups. The term "reactive" in this context indicates that these groups are present preferably on an external surface of the particle, and 20 are not hindered by other functional groups, thereby allowing the cross-linking reactions comprehended by the present invention to occur. agent delivery irrespective of their 3-dimensional shape or conformation. The 25 particles of the invention may be such that they fully or partially encapsulate the pharmaceutical agent or entrap the pharmaceutical agent within the polymer matrix of the particle. Particles previously classified as either micro- or nanopanicies are included within this definition, so that average particle diameter may vary from between about 10 nm and 900 ^m. For example, 30 particles intended to act as implants which will be localised in a particular area of the body for controlled release of the pharmaceutical agent may appropriately have average diameter of 400-800 /an, whereas particles requiring internalisation by cells or transport across the gastrointestinal mucosa will have average diameter less than about 10 gm. In contrast, particles administered 35 subcutaneously may appropriately be larger than 10 ^m in average diameter to prevent the particles re-entering the general circulation.
The shape and 3-dimensional conformation of the particle used will depend on the intended utility of the particle concerned. Specifically, particle 40 shape ' :n based upon knowledge of the 3- The cross-linking techniques according to the present invention can be The term "particle" encompasses all particles for pharmaceutical INTELLECTUAL PROPERTY OFFICE OF N.Z. dimensional shape or conformation of the pharmaceutical agent that is to be delivered.
The following documents, which are incorporated herein by reference in 5 their entirety, refer to various types of particles that can be used or modified for use in relation to the present invention. This list of documents and the types of particles disclosed therein is not intended to be exhaustive. United States Patent No. 5,352,461; International Patent Publication No. WO 88/01213; Bergeron et al., J. Am. Chem. Soc., 1995, 117, 6658-6665; International Patent Publication 10 No. WO 96/29991; European Patent No. 6712169; and U.S. Patents No. 4,835,248; and No. 5,041,291.
In general terms, and again without limiting the intended scope of the invention in any way, particles for delivery of pharmaceutical agents can be IS formed via a number of methods, several of which are outlined below: (i) Solvent Evaporation In this technique a compound which is soluble in one solvent is dispersed into a non-miscible solvent and the first solvent is evaporated off. Particles 20 formed in this fashion have been used to administer parenterally a number of water insoluble compounds. An example of such a system would be the formation of polylactic -glycolic acid nanoparticles in which the antifungal agent, griseofulvin is entrapped. (ii) Desolvation In this method a compound is dissolved in a first liquid (the solvent) and a second liquid (which is miscible with the first liquid, but in which the compound is not soluble) is added to the solvent. As more of the second liquid is added the compound becomes desolvated. During the process of desolvation 30 the compound rich phase (the coacervate) contains an enriched amount of compound which is dispersed as microdroplets in the compound deficient phase. At this stage the coalesced material can be chemically cross-linked by a suitable cross-linking agent to form micro- or nanoparticles. Nanoparticles of gelatin or BSA can be prepared in this way. Solutions of these proteins are desolvated by 35 the addition of sodium sulfate, or ammonium sulfate solutions. At the point of desolvation there is an increase in turbidity, at which time the nanoparticles can be formed by the addition of a suitable cross-linker such as glutaraldehyde or butanedione. (iii) Complex Coacervation In this procedure two polyelectrolytes having opposite charge are mixed in aqueous medium so that a spontaneous liquid/liquid phase separation occurs. The phenomenon is limited to polymers having a suitable ionic charge density 5 and chain length. Typically these microspheres are formed by the addition of a polyanion such as polyglutamic acid, carboxymethyl cellulose, gum Arabic, alginate, or polyphosphate, to a polycation such as gelatin or polylysine. (iv) Polymer/Polymer Incompatibility This procedure is based upon the observation that two chemically different polymers dissolved in a common solvent usually are incompatible. Thus the mixture will tend to form two phases. The insoluble phase can be used to coat core particles to form microcapsules. An example would be the precipitation of ethyl cellulose from cyclohexane by the addition of 15 polyethylene. (v) Interfacial Polymerization In this technique, two reactants, each dissolved in a mutually immiscible liquid, diffuse to the interface between the two liquids where they react to form 20 a capsule wall. An example of such capsule formation would occur if a mixture of Sebacoyl chloride dissolved in an oil phase was emulsified into an aqueous phase containing ethylenediamine.
As can be seen from the above description various different classes of 25 polymers are capable of forming particles that can be used for pharmaceutical agent delivery.
The process of cross-linking of particles according to the invention is effected by reaction between carboxyl, hydrazidyl, amino and/or thiol groups 30 on the polymer or polymers, which form the particle, with a spacer which comprises two or more carboxyl, hydrazidyl, amino and/or thiol groups groups, with the reaction typically being catalyzed by the presence of at least one carbodiimide. Preferred cross-linking reactions include: generation of hydrazide bonds between a hydrazide and a carboxyl group; generation of an 35 amide between an amine and a carboxyl group; generation of a thioester between a carboxyl group and a thiol group; and generation of a disulfide between two thiol groups. It will be clearly understood by a person skilled in the art that if the polymer or polymers of the particle system chosen do not include reactive carboxyl, hydrazidyl, amino and/or thiol groups, they will need 40 to be chemically modified in order to do so. In a typical reaction a polymer containing carboxyl groups can be substituted with hydrazidyl groups by the reaction of the polymer with a dihydrazidyl spacer and a suitable carbodiimide (See example 7 and 8, and Russell-Jones et al., Bioconjugate Chemistry, 6, 459-465).
Polymers suitable for use in the invention include, but are not limited to: poly-amino acids such as polyglutamic acid, polyaspartic acid, and polylysine; poly(N-acylhydroxypropine esters; polysebacic acid; polyfumaric acid; polylactic acid; polyglycolic acid; polylactic-co-glycolic acid; 10 carboxymethylcellulose; gum arabic; alginate; polyphosphate; heparin; gelatin; copolymers of sebacic acid and fumaric acid; copolymers of biscarboxyphenoxypropane and sebacic acid; poly(carboxyphenoxyacetic) acid; poly(carboxyphenoxyvaleric) acid; poly-e-caprolactone and. related polyesters (poly-e-caprolactone-co-5-valerolactone; poly-e-caprolactone-co-DL-lactic acid; is hyaluronic acid; chitin; chitosan; dextran; carboxy-dextran; collagen; albumin; fibrinogen; and other naturally occurring polymers.
Scheme 1 shows an example of a reaction scheme contemplated by the present invention. In this scheme the tricarboxylic acid, citric acid, first is 20 reacted with a 2 fold molar excess of ED AC and NHS. The resultant disuccinimidyl ester is then reacted with an adipylhyrazide-modified polymer to form a covalently cross-linked polymer (See example 8).
Scheme 1 o o II ch2c—o—n + 2-edac/2-nhs ch2cooh ch2c-o-n II o Citric acid bis modified Poly[glu-co-adipylhydrazidegl Poly[glu-co-adipylhydrazideglu] Citric acid O O 0 0 CH,COOH J - U ■■oit —(NH-CHC)—(NH-CH-C)^- CH * —(NH-CH-C)—(NH-CH-C)y— + HOCCOOH + 2-EOAC/2-NHS cHj CH2 CHj CHjCOOH " C=0 C=( CH2 CH2 OH NH c=o c=o NH OH NH C=< NH (CHj C=0 OH C=t (CH2)4 O C=0 NH C=0 NH—C-CH2"C-CH2-C-NH NH NH OH O NHj c=o c=o I NH NH OH c=o c=o CHa CH, CHj CHa —JNH-CH-Cfc-JNH-CH-CJj-O O The following scheme 2 shows another example of a general reaction scheme contemplated by the present invention. In scheme 2 the carboxylic acids on the polymer are reacted with EDAC in the presence of V& Mole equivalent of adipyldihyrazide to form a covalently cross-linked polymer (See example 3).
Scheme 2 Bis modified adipylhydrazide-polyglutamic acid Polyglutamicacid o o -NH-CH-C—NH-CH-C- I CH2 CH, c=o OH I CHa CHa c=o I OH Adipyldihydrazide NH2 NH c=o (CHj), c=o l NH NH2 ♦ 2-EDAC O II —NH-CH-C -I CHj CHa c=o I OH O -NH-CH-C-CHj CHa C=0 I NH i NH i c=o (CHa)« c=o NH NH I c=o CH, I CH2 I OH c=o i CH2 I CH2 I —NH-CH-C—NH-CH-C— ii ii o o PCT/IB98/0I464 According to the present invention, there are no particular limitation to the type of carbodiimide that can be used within the present invention, although some particularly preferred carbodiimides are N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide (known as EDC or EDAC), NN'-5 dicyclohexyl-carbodiimide (DCC), N'-diisopropyl-carbodiimide, N'N'-di-tert-butylcarbodiimide l-cyclo-hexyl-3-(4-diethylaminocycIohexyl)carbodiimide, 1,3-di-(4-diethylaminocyclo-hexyl)carbodiimide, 1 -cyclohexyl-3-(- diethylaminoethyl) carbodiimide, l-cyclohexyl-3-(2-morphoIinyl-(4)-ethyl)carbodiimide, 1 -cycIohexyI-3-(4-diethyl-aminocyclohexyl) carbodiimide 10 (Sheehan et al, J. Org. Chem., 21, 439-441 (1956)). Indeed any 'coupling agent' can be used that generates an active ester e.g. BOP, PyBOP, TSTU, HBTU, TBTU, HBPyU, DPPA, IIDQ, EEDQ. These coupling agents are well known in the field of peptide synthesis. is The dihydrazide spacers comprehended by the invention include, but are not limited to, those which accord with general formula I, as follows: NH2NHCO-R-CONHNH2 Formula I wherein R represents a direct bond, or a straight, branched chain or cyclic alkyl, alkenyl, alkynyl or aryl. R preferably contains up to 10 carbon atoms.
Preferred dihydrazides are selected from, but not limited to: oxalic dihydrazide, malonic dihydrazide, malic dihydrazide, norbornene dihydrazide, 25 Phthalic dihydrazide, tartaric dihydrazide succinic dihydrazide, glutaric dihydrazide, adipic dihydrazide, maleic dihydrazide, fumaric dihydrazide or butadienoic dihydrazide. Hydrazine also may be used.
Carboxylic acid spacers which can be utilized according to the present 30 invention include: malonic acid, maleic acid, citric acid, glutamic acid, aspartic acid, succinic acid, adipic acid, glutaric acid, ,dimethylglutaric acid, oxalic acid, fumaric acid, phthalic acid, tartaric acid, isophthalic acid, terephthalic acid and the branched alkyl derivatives thereof.
It also is possible for the spacer to include more than two carboxyl, hydrazidyl, amino and/or thiol groups, or even combinations of carboxyl, hydrazidyl, amino and/or thiol groups, depending upon the nature of the reactive groups present on the polymer/s. That is, if only carboxyl reactive groups are present on the polymer/s then a spacer comprising only hydrazidyl, 40 amino, or thiol reactive groups may be employed, and vice versa. If the polymer(s) include, for example, both carboxyl and hydrazidyl groups it may be appropriate for the spacer also to comprise both of those reactive groups.
In general terms, the conditions that must be employed in effecting the 5 cross-linking reaction are simply to provide approximately molar equivalents of the spacer and carbodiimide, depending upon the level of cross-linking that is required. It is then necessary to leave the reaction for between about two and 24 hours, preferably at least four hours, in order for the cross-linking to progress to completion. The cross-linked encapsulating particle can be 10 recovered by dialysis against distilled water, or other suitable buffers such as PBS, saline, Hepes, etc.
The pharmaceutical agent can be incorporated within the particle at the time of formation of the particle, preferably by including the pharmaceutical IS agent within the mixture of components required to produce the particle. Alternatively, in cases such as the formation of nanoparticles via polyelectrolyte complexation, the pharmaceutical agent can be included in either the polycation or polyanion phase, depending upon its solubility, and the mixture can be slowly added to the precipitating phase (See example 1 and 2) In a preferred embodiment of the invention the spacer includes a biodegradable linkage that can be degraded in a controlled manner under particular circumstances. For example, it is possible to incorporate into the spacer linkage units that will be cleaved in a defined environment such that the 25 biodegradable linkage will be cleaved in order that the particle releases its entrapped pharmaceutical agent. These biodegradable linkages can be tailored specifically to enable cleavage of the linkage in the desired environment. Examples of some biodegradable linkages include disulphide bonds, azo groups and esters that can be cleaved under defined conditions. Suitable thiol-cleavable 30 linkers include cystamine, cystine, and oxidized glutathione, the latter two of which can be activated with NHS and a carbodiimide and then used to cross-link hydrazidyl groups Other thiol-cleavable cross-linkers which can be reacted directly with pendant hydrazidyl groups include, amongst others, Bts-[P-(4-azidosalicylamido)ethyl]disulfide, Dithioto-(succinimidyl propionate), 35 Dimethyl 3,3'-dithio6ispropionimidate, 3,3'-Dithio£w(sulfosuccinimidyl propionate), Sulfosuccinimidyl 2-(m-azido-o-nitrobenzamido)ethyl-l ,3'-dithiopropionate, N-Succinimidyl 6-(4'-azido-2'-nitrophenyl-amino)hexanoate and Sulfosuccinimidyl-2-(p-azido-salicyIamido)ethyl-1,3-dithio-propionate.
Suitable esterase cleavable linkages include those formed from the 2-aminoethyl esters of the known amino acids, including the 2-aminoethyl ester of glycine, 2-aminoethyl ester of phenylalanine, and their disuccinimidyl derivatives, including N,N'-disuccinimidyl-(2-amino-2-benzyl-ethanoate, N,N'-5 dissuccinimidyl-2-amino-ethyl-ethanoate, and ethylene glycolbis[succinimidylsuccinate] In accordance with another embodiment of the present invention it is possible for the cross-linked particles according to the invention to be linked to 10 compounds (hereinafter referred to as "targeting compounds") which are actively absorbed across the gastrointestinal mucosa or bound to intestinal epithelial cells. For example, the particles according to the invention could be linked to vitamin B12 or an analog thereof which will allow them to bind to intrinsic factor (IF), allowing the complex to be actively taken up from the is intestine. Use of such targeting compounds is described in WO 87/02251,. PCT/AU94/00273 and PCT/AU94/00274, which are incorporated herein by reference in their entirety.
The particles according to the invention also can be linked to viral 20 adhesins, bacterial pili, toxin binding subunits, haemagglutinins, lectins or bacterial invasins which are generally present on the surfaces of bacteria and viruses and which are capable of specific binding to the intestinal epithelium. Binding to these agents therefore results in intestinal epithelial targeting (to delay transit of pharmaceutical agents down the intestine), or it can result in 25 eliciting uptake and transcytosis of the targeting molecule and attached pharmaceutical across the intestinal epithelial cell wall.
Some examples of bacterial adhesins include proteins isolated from various Streptococcal species such as the IgA binding proteins (ARP2, ARP4, 30 bac; Fischetti,. ASM News, 62, 405-410 (1996)), the IgA binding protein from Group B streptococci (Russell-Jones et al., 1984); protein antigens of Group B streptococci with special reference to the ibc antigens, Russell-Jones et al, J. Exp. Med., 160, 1476-1484 (1984); fibrinogen binding proteins (Mrp4, Sfb, PrtF, fiibA, fhbB, FnBP, FnBp; Fischetti, 1996, ibid), as well as the collagen 35 binding factor (cna) and clumping factor (clfA) from S. aureus.
Other structures shown to be responsible for adhesion of bacteria to epithelial surfaces are the filamentous surface adhesins or pili. These adhesins include the K88, K99 (Mouricout, et al.. Infect. Immun., 58, 98-106 (1990)), 40 F41 and 987P pili found on E. coli inhabiting neonatal calves and piglets, the CFA1 and CFAII pili found on E. coli strains causing diarrhoea in human, and Pseudomonas aeruginosa PAK pilus (Irvin et al.,. Infect. Immun., 57, 3720-3726 (1989)) Doig et al., Infect. Immun., 58, 124-130 (1990)) There is also the type "P" pili isolated from E. coli strains associated with human 5 pyelonephritis (Isberg,. Science, 252, 934-938 (1991)). Type I and type 2 fimbriae found on A. viscosis and A. naeslundii (respectively) also have potential roles in adherence and subsequent internalization of these bacteria (Fischetti, 1996, Ibid). Similarly, a 36 kDa protein on the surface of N. gonorrhoeae has been implicated in the binding of these organisms to surface 10 lactosylceramides on human epithelial cells and may be responsible of uptake of these organisms by the epithelial cells (Paruchuri, et al., Proc. Natl. Acad. Sci. USA, 87, 333-337 (1990)).
Many bacteria possess surface structures apart from pili that have been 15 shown to be responsible for the epithelial invasion of these bacteria, known as bacterial invasins, which could be used according to the invention. For instance, Internalin, a surface protein encoded by the inlA gene of L. monocytogenes is responsible for internalization of Listeria within intestinal epithelial cells (Cossart, J. Cell. Biochem. Suppl. B001, pp 36 (1994)) Falkow 20 CeU, 65, 1099-1102 (1991))\ Mengaud et al., Cell, 84, 923-932 (1996)) Lingnau et al., Infect. Immun., 63; 3896-3903 (1995)); Drevets et al., Irtfect. Immun., 63; 4268-4276 (1995)). Internalization of Listeria is triggered following binding of intenalin to E-cadherin on epithelial cells (Falkow, 1991, ibid] Mengaud, etal., 1996, ibid). A protein with similar function to internalin 25 is found on the surface of Yersinia pseudotuberculosis; this protein, invasin, is a 986 amino acid protein located in the Y. pseudotuberculosis outer membrane (Falkow, (1991), ibid; Isberg (1985) ibid. A single genetic locus encoded by Yersinia pseudotuberculosis permits invasion of cultured animal cells by Escherichia coli K-12). Expression of this protein on the surface of other gram 30 negative bacteria such as E. coli K12 enables these cells to efficiently attach to and become internalized by epithelial cells (Falkow, (1991), ibid\ Isberg et al (1985), ibid. Similarly latex particles coated with internalin are internalized by cultured mammalian cells. Isberg, (1991). A second protein from Y. pseudotuberculosis, the ail gene product, is responsible for binding of these 35 organisms to many eukaryotic cells but only promotes uptake in a few cell types. Id.
Other structures/proteins suitable for linkage to the particles of the invention, include surface proteins from many viruses that are known to gain 40 access to the intestinal or respiratory epithelium following binding of surface PCT/IB98/0I464 structures on the virus known as viral haemagglutinins. Such specific binding proteins have been shown on the surface of rotaviruses (VP7), adenoviruses, Norwalk virus, (Fukuhara et al,,. J. Virol., 62, 2209-2218 (1988)); Yolken, in Lennette (Ed.) Vol. 6; 273-291 (1985)). Similarly surface haemagglutinins also 5 have been implicated in inducing acid-induced fusion of viruses to membranes following initial binding and uptake of influenza (Wharton et al, J. Biol. Chem., 263; 4474-4480 (1988)).
Other haemaggiutinin molecules exist on the surface of viruses such as 10 rotavirus, which aid in the binding, internalization and transcytosis of these viruses across intestinal epithelial cells (Keljo et al., J. Ped. Gastroenterol. Nutrition, 7, 249-256 (1988)). Evidence suggests, however, that following binding of some viruses to the endocyte, the surface haemagglutin may be cleaved to yield a fusogenic protein which in turn enables the virus to enter the 15 cell by direct cell membrane penetration, rather than by endocytosis (Kaljot et al., J. Virol, 62, 1136-1144 (1988)); Fukuhara, et al., (1988), ibid). Such molecules may have some utility in targeting pharmaceuticals to intestinal epithelial cells, but may not be suitable for delivery of the pharmaceutical to the circulation as the endocytosed material may not be transcytosed.
Apart from the mucosal uptake and transport of adhesins such as pili and viral haemagglutins, it has also been found that it is possible to covalently link molecules to the binding subunits of various toxin and plant lectins and lo elicit uptake of the linked molecules following oral administration. Toxins of most 25 relevance to initiate receptor-mediated uptake according to the invention are those that consist of an ABn subunit structure in which the A subunit is responsible for toxicity, while the B subunit functions as the specific binding unit of the toxin. These toxins include the cholera toxin-like molecules such as E. coli heat-labile toxin, cholera toxin, Campylobacter jejuni heat-labile toxin, 30 C. botulinum C2 toxin, tetanus toxin, diphtheria toxin and Pseudomonas exotoxin A (Sears etal,. Microbiol. Rev. 60, 167-215 (1996)); Waksmaa etal, Biochem. Biophys. Acta., 604, 249-296 (1980), verotoxin, Shiga-toxin (Okerman, Veterinary Microbiol., 14, 33-46 (1987)). All of these toxins share a common property in that they must first bind-to and then cross membranes to 35 exert their toxic activity. It is the ability of these toxins to bind to and be internalized by epithelial cells, which makes these molecules suitable vehicles for transporting molecules into and across epithelial cells.
A number of plant toxins of the general structure AB also have been 40 identified to have the potential to bind to cells and be internalized, and are WO 99/11703 PCT/IB98/01464 suitable molecules for targetting according to the invention. All of these toxins are active orally and as such have the ability to bind to and be internalized by enterocytes. These toxins include ricin, abrin, viscumin, modeccin and volkensin that bind to D-galactose (Stirpe et al., FEBS, 195, 1-8 (1986))).
Other A-B toxins which could potentially bind to intestinal epithelial cells and cause uptake include botulinum toxin (from C. botulinum) (Blaustein et al., FEBS, 225, 7/5-720(1987)).
Importantly, this invention also relates to a method of controlled drug ]0 release within a patient, which patient is administered a composition comprising a pharmaceutical agent which is entrapped or encapsulated by a cross-linked particle according to the invention. In its broadest sense, this method can be used for the therapy, prophylaxis or diagnosis of any vertebrate animal, although it is preferred that the animal concerned is a mammal. Particularly 15 preferred are laboratory animals such as mice, guinea pigs, rabbits, domestic animals such as cats and dogs, farm animals such as horses, cattle, sheep, goats, pigs, captive wild animals such as lions, tigers, elephants or primates such as humans, chimpanzees, baboons and apes.
The effective amount of the pharmaceutical agent delivered when provided in combination with the cross-linked particles of the invention depends upon numerous factors. The nature of these factors will readily be apparent to a person skilled in the art. For example, relevant factors include the type, age and sex of the vertebrate animal concerned, the disorder that the animal is 25 suffering from or is prone to suffer from, the height and weight of the animal, and the type of pharmaceutical agent that is being delivered. The dose also will depend upon whether the cross-linked particles are linked to other agents that aid uptake, as well as upon the stability of the particle and the level of control over release of the entrapped or encapsulated pharmaceutical agent, which will 30 be related to the nature and extent of cross-linkage. When all of these factors are taken into consideration by a person skilled in the art, the appropriate dose can be determined. Routine dosage regimens that can be used to determine the optimum or appropriate dosage of the pharmaceutical agent are well known to those of skill in the art.
The compositions according to the invention also may be administered in conjunction with one or more pharmaceutically suitable carriers and/or excipients. The nature of the carrier or excipient substance will depend upon factors such as the route of administration, the nature of the cross-linked 40 particle, and the nature of the pharmaceutical agent concerned. A complete discussion of appropriate pharmaceutical carriers and excipients is provided in the HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, Second Edition, 1994, Wade and. Weller (Eds.), The Pharmaceutical Press, London, which is incorporated herein by reference in its entirety.
As described above, the compositions according to the invention can be administered via either enteral or parenteral routes of administration. In a preferred embodiment of the invention, administration is via the oral route although, for example, rectal administration or direct administration to the 10 stomach or small intestine also is possible. In addition, the compositions according to the invention can be administered intramuscularly, intraperitoneally, subcutaneously, optically, aurally, vaginally, topically, directly into an organ or via other parenteral means. The skilled artisan will appreciate that administration via these means requires that the composition be is provided in a suitable dosage form with appropriate carriers and/or excipients, as described in the Handbook of Pharmaceutical Excipients, supra.
The present invention, thus generally described, will be understood more readily by reference to the following examples, which are provided by way of 20 illustration and are not intended to be limiting of the present invention.
Example 1 Synthesis of nanoparticles containing insulin via polyelectrolyte complexation using gelatin and carboxymethyl cellulose Carboxymethyl cellulose (low viscosity, 50-200 cps) was dissolved at 2S 5% in distilled water (DW) and the pH adjusted to pH 3.9 with 1 M HC1. Gelatin (Bloom 175) was dissolved at 5% in DW and the pH adjusted to 3.9 with 1 M HC1. Insulin was dissolved at 20 mg/ml in 20 mM HC1 and 400 jil added to 4.0 ml gelatin which had been heated to 60 °C. The insulin/gelatin mix was slowly added to 2.0 ml of carboxymethyl cellulose (5%) whilst stirring 30 vigorously. Stirring was continued for 15 minutes at which time 12 ml DW was added. Adipyl hydrazide (48 mg at 100 mg/ml in DW) was added to the solution followed by 48 mg EDAC (100 mg/ml). The solution was stirred for more than 4 hours, followed by exhaustive dialysis against DW.
Example 2 Preparation of Gelatin/Polyglutamate nanoparticles which contain insulin via polyelectrolyte complexation Polyglutamate (17,500 MW) was dissolved at 0.25% in distilled water (DW) and the pH adjusted to pH 3.9 with 1 M HC1. Gelatin (Bloom 175) was dissolved at 1.0% in DW and the pH adjusted to 3.9 with 1 M HCI. Insulin was dissolved at 20 mg/ml in 20 mM HC1 and 350 added to 4.0 ml gelatin which had been heated to 60°C. The insulin/gelatin mix was slowly added to 4.0 ml of 0.25% Polyglutamate, whilst stirring vigorously. Stirring was continued for 15 minutes at which time 8 ml DW was added. Adipyl hydrazide 5 (5 mg at 100 mg/ml in DW) was added to the solution followed by 5 mg EDAC (100 mg/ml). The solution was stirred for more than 4 hours, followed by exhaustive dialysis against DW.
Example 3 Preparation of Gelatin/alginate nanoparticles which contain 10 insulin via polyelectrolyte complexation Sodium alginate (low viscosity, 250 cps) was dissolved at 1.25% in distilled water (DW) and the pH adjusted to pH 3.9 with 1 M HC1. Gelatin (Bloom 175) was dissolved at 1.25% in DW and the pH adjusted to 3.9 with 1 M HC1. Insulin was dissolved at 20 mg/ml in 20 mM HC1 and 1.0 ml added to 15 5.0 ml gelatin which had been heated to 60 ^C. The insulin/gelatin mix was slowly added to 10.0 ml of alginate (1.25%), whilst stirring vigorously. Stirring was continued for 15 minutes at which time 15 ml DW was added. Adipyl hydrazide (60 mg @ 100 mg/ml in DW) was added to the solution followed by 60 mg EDAC (100 mg/ml). The solution was stirred for more than 20 4 hours, followed by exhaustive dialysis against DW.
Example 4 In vivo release of insulin from gelatin/CMC polyelectrolyte complex nanoparticles following intravenous injection in rats Male Wistar rats were placed in a restraining apparatus and a blood 25 sample obtained from the tail vein of the conscious rats. The rats were then injected intravenously with a saline solution containing either 100 fig dose of insulin or a preparation of gelatin/CMC nanoparticles containing 100 fig of insulin. At 60, 120, 180, 240 and 300 minutes following injection the rats were from the tail vein. The collected blood was allowed to clot at 4°C, after which 30 the serum was separated from the clot via centrifugation. Blood glucose levels were obtained using a standard glucose assay such as that sold by Sigma (0GAGO-2O). Results are shown in Figure 1.
Example 5 Modification of insulin release from polyelectrolyte complex 35 (PEC) nanoparticles by varying the concentration of EDAC and adipyl hydrazide The rate of release of insulin from PEC nanoparticles was modified by altering the concentration of EDAC and adipyl hydrazide used in cross-linking the PEC nanoparticles formed by any of the above procedures. Release rates 40 were increased by reduction in concentration of the cross-linkers; conversely, increasing the concentration of cross-linkers decreased the release rates (See Figure 2).
Example 6: Preparation of hydrazidyl-polyglutamic acid 5 Polyglutamate was dissolved at 25.8 mg/ml in DW. Adipyl hydrazide (87 mg/ml in DW) was added to the polyglutamate at 2:5 volume:volume ratio. Solid EDAC (4 mg/ml of Polyglutamate) was added to the solution and allowed to react for 2 hours. The resultant solution was dialysed extensively against DW and lyophilized.
Example 7 Preparation of hydrazidyl-carboxymethyl cellulose Carboxymethyl cellulose was dissolved at 25 mg/ml in DW. Adipyl hydrazide (87 mg/ml in DW) was added to the polyglutamate at 2:5 volume: volume ratio. Solid EDAC (4 mg/ml of Carboxymethyl cellulose) was 15 added to the solution and allowed to react for 2 hours. The resultant solution was dialysed extensively against DW and lyophilized.
Example 8 Preparation of PEC nanoparticles containing insulin and formed with adipylhydrazidyl-polyglutamic acid and gelatin 20 Adipyl-hydrazidyl-Polyglutamate was dissolved at 2.5 mg/ml in DW and the pH adjusted to pH 3.9 with 1.0 M HC1. Insulin was dissolved at 20 mg/ml in 20 mM HC1 and added to a solution of Gelatin (Bloom 175; 10 mg/ml in DW, pH 3.9) which had been heated to 60°C, to give a solution of 0.8 mg/ml insulin in gelatin. The solution was added to an equal volume of a warm 25 solution (60 C) of adipyl-hydrazidyl-PoIyglutamate while stirring rapidly. After stirring for 15 minutes the solution was diluted 1:3 in DW. Citric acid (100 mg/ml) was mixed with an equal weight of NHS (100 mg/ml in acetone) and the NHS-ester formed by reaction with a 2-fold weight excess of EDAC. Following 10-minute activation the NHS2~citrate was added to the 30 microparticles at a weight equal to that of the adipyl-hydrazidyl-Polyglutamate. The reaction was allowed to proceed overnight, after which the material was dialyzed extensively against DW.
Example 9: Preparation of PEC nanoparticles containing insulin and formed 35 with hydrazidyl-carboxymethyl cellulose and gelatin Adipyl-hydrazidyl-Carboxymethyl cellulose was dissolved at 25 mg/ml in DW and the pH adjusted to pH 3.9 with 1.0 M HC1. Insulin was dissolved at 20 mg/ml in 20 mM HC1 and added to a solution of gelatin (Bloom 175, 8mg/ml in DW, pH 3.9) to give a solution of 0.8mg/ml insulin in gelatin. The 40 solution was added to half volume of a warm solution (60°C) of adipyl- hydrazidyl-Carboxymethyl cellulose while stirring rapidly. After stirring tor 15 minutes the solution was diluted 1:3 in DW. Citric acid (100 mg/ml) was mixed with an equal weight of NHS (100 mg/ml in acetone) and the NHS-ester formed by reaction with a 2-fold weight excess of EDAC. Following 10 minute activation the NHS2-cicrate was added to the microparticles at a weight equal to that of the adipyl-hydrazidyl-Carboxymethyl cellulose. The" reaction was allowed to proceed overnight, after which the material was dialyzed extensively against DW.
Example 10: Preparation of 2-aminoethvl-2-aminoethanoate (AEAE) (a) Coupling of Boc-glycine with Boc-ethanoiamine BOCHN-^^0" + CDI/DIEA HOOC NHBOC BocHN T NHBoc Boc-glycine (12.0 g, 0.068 mol) and carbonyl diimidazole (12.1 g, 0.074 mol) were dissolved in DMF (50 mL) with vigorous evolution of COi and the solution stirred at room temperature for 1 h. A solution of Boc-ethanolamine (10.0 g, 0.062 mol) in DMF (10 mL) was added dropwise to the 20 active ester solution followed by DIEA (11.9 mL, 8.80 g, 0.068 mol) and stirring was continued at room temperature overnight. The solution was poured into water (200 mL) and extracted with ether (3 x 75 mL), washed with saturated sodium hydrogen carbonate solution (1 x 100 mL), dried (MgSO«) and the solvent removed to give the product (18.1 g, 92 %) as a colourless oil which 25 was used without further purification. (b) Removal of Boc protecting group and succinylation The crude di-Boc ester (22.9 g, 0.072 mol) was dissolved in trifluoroacetic acid (20 mL) at 0° with the vigorous evolution of COi and the 30 solution stirred at 0° for lh. The trifluoroacetic acid was removed under reduced pressure, the residue dissolved in acetonitrile (30 mL) and the solvent removed again. The crude bis-TFA salt was dissolved in THF (20 mL) and solid anhydrous potassium carbonate (20 g) was added and the mixture stirred at room temperature for lh. The solution was dried (Na2S04) and the solution 35 filtered into a solution of succinic anhydride (22.7 g, 0.23 mol) in THF (120 mL). DIEA (30 mL, 22.3 g, 0.17 mol) was added to give a basic solution and stirring was continued at room temperature. At lh intervals, two aliquots of DIEA (5 mL, 3.70 g, 0.029 mol) were added and stirring was continued for 24 h. Most of the THF was removed under reduced pressure and the suspension SUBSTITUTE SHEET (RULE 26) was poured into two phase saturated sodium hydrogen carbonate solution (200 mL) and ethyl acetate (100 mL). The organic layer was removed and the aqueous layer was reextracted with ethyl acetate (100 mL). the aqueous layer was acidified to pH ~ 1 with hydrochloric acid (10 M) and extracted with ethyl 5 acetate (3 x 150 mL), dried (NaaSO*) and the solvent removed. The residue was suspended in ether (50 mL), cooled to 0° and filtered to give the product . (6.01 g, 25 %) as minute needles. (c) Preparation of dihydrazidyl ester cross-linker CH 1) BocNHNH 2/PyBOP 2) TFA NH2NH II - II NHNH2 To a solution of the foregoing diacid (987 mg, 3.10 mmol) in DMF (20 mL) was added PyBOP (3.72 g, 7.15 mmol) and f-butyl carbazate (950 mg, 15 7.19 mmol) followed by DIEA (2.20 mL, 1.65 g, 0.013 mol) and stirring was continued at room temperature overnight. The solution was poured into saturated sodium hydrogen carbonate solution (100 mL) and extracted with ethyl acetate (3 x 50 mL), dried (MgSO-0 and the solvent removed to leave an oil which was dissolved in TFA (10 mL) and stirred at room temperature for lh.. 20 Ethanol was added (20 mL) and the solvents removed under reduced pressure to give the dihydrazide as a yellow oil (506 mg, 47 %).
Example 11: Preparation of 2-aminoethyl-2-amino-2-benzyl-ethanoate(AEABE) (a)Coupling of Boc-phenylalanine with Boc-ethanolamine .Ph RnrHN,/\X-°H + CDI/DIEA HOOC NHBOC *• BOCHN Boc-phenylalanine (15.7 g, 0.059 mol) and carbonyl diimidazole (10.1 g, 0.062 mol) were dissolved in DMF (60 mL) with vigorous evolution of CCh and the solution stirred at room temperature for 1 h. A solution of Boc-ethanolamine (9.35 g, 0.058 mol) in DMF (10 mL) was added dropwise to the Rl IRSTITIITP CHPFT /Rl II F 9fi\ active ester solution followed by DIEA (12.0mL, 8.9 g, 0.069 mol) and stirring was continued at room temperature overnight. The solution was poured into water (200 mL) and extracted with ether (3 x 75 mL). washed with saturated sodium hydrogen carbonate solution (I x 100 mL), dried (MgSOO and the solvent removed to give the product (18.13 g, 92 %) as a colourless oil which eventually solidified and was used without further purification. (b) Removal of Boc protecting group and succinylation BocHN The crude di-Boc ester (9.83 g, 0.024 mol) was dissolved in trifluoroacetic acid (20 mL) at 0° with the vigorous evolution of COi and the 15 solution stirred at 0° for lh. The trifluoroacetic acid was removed under reduced pressure, the residue dissolved in acetonitrile (30 mL) and the solvent removed again. The crude bis-TFA salt was dissolved in THF (20 mL) and solid anhydrous potassium carbonate (20 g) was added and the mixture stirred at room temperature for lh. The solution was dried (NaaSO<) and the solution 20 filtered into a solution of succinic anhydride (4.98g, 0.050 mol) in THF (30 mL). DIEA (20 mL, 14.8 g, 0.11 mol) was added to give a basic solution and stirring was continued at room temperature for 24 h. Most of the THF was removed under reduced pressure and the suspension was poured into two phase saturated sodium hydrogen carbonate solution (200 mL) and ethyl acetate (100 25 mL). The organic layer was removed and the aqueous layer was re-extracted with ethyl acetate (100 mL), the aqueous layer was acidified to pH — 1 with hydrochloric acid (10 M) and extracted with ethyl acetate (3 x 150 mL), dried (Na2SO<) and the solvent removed. The residue was recrystallised from ethyl acetate/hexane to give the product (2.04 g, 22 %) a colourless powder.
Example 12: Synthesis of nanoparticles containing insulin using Isobutvlcvanoacrvlate (IBCA) and carboxymethyl cellulose Insulin was dissolved at 100 mg/ml in 0.1 M HC1. An aliquot of insulin 35 (120 /zl) was mixed with an equal volume of miglyol. The solution was vortexed rapidly, 12 ml ethanoi was added and the solution vortexed again. Finally, 120 /xl IBCA was added and the solution slowly dripped into 24 ml of 0.25% PE6800. After 15 minutes 6 ml of 0.25 % CMC was added to the solution SUBSTITUTE SHEET (RULE 26) WO 99/11703 PCT/IB98/01464 which was allowed to stir for a further 90 minutes. The solution was then split into two equal volumes and 24 mg of adipyldihydrazide (AH) plus 48 mg EDAC was added to one solution. The particles were allowed to cross-link overnight before being tested in rats. As can be seen in Figure 3. Addition of 5 EDAC and AH to the nanoparticles greatly reduced the rate of release of insulin, as judged by modification of serum glucose.
Example 13 Preparation of polyelectrolyte nanoparticles containing insulin cross-linked with esterase-cleavable AEABE 10 Adipyl-hydrazidyl-Carboxymethyl cellulose was dissolved at 2.5 mg/ml in DW and the pH adjusted to pH 3.9 with 1.0 M HC1. Insulin was dissolved at 20 mg/ml in 20 mM HC1 and 8 mg added to 2 ml of a solution of 2.5 mg/ml gelatin (pH 3.9). The solution was added to 16 ml of a warm solution (60 °C) of adipyl-hydrazidyl-Carboxymethyl cellulose while stirring rapidly. After 15 stirring for 15 minutes the solution was split into 4 equal samples. AEABE (40 mg @100 mg/ml) was mixed with 30 mg NHS (100 mg/ml in DMF) and the NHS-ester formed by reaction with 60 mg EDAC. Following 10 minute activation 20, 10 and 5 mg aliquots of the (NHS)2~AEABE were added to the nanoparticles. The reaction was allowed to proceed overnight, and was then 20 tested following intravenous administration to rats. As shown in Figure 4, addition of increasing quantities of the esterase cleavable cross-linker resulted in decreasing release of insulin in vivo.
Example 14: Oral administration of IBCA nanoparticles containing insulin cross-linked with esterase-cleavable AEABE Insulin was dissolved at 100 mg/ml in 0.1 M HC1. An aliquot of insulin (120 fil) was mixed with an equal volume of miglyol. The solution was vortexed rapidly, 12 ml ethanol was added and the solution vortexed again. 30 Finally, 120 /xl IBCA was added and the solution slowly dripped into 24 ml of 0.25 % PE6800. After 15 minutes 6 ml of 0.25 % adipyl-hydrazidyl-CMC was added to the solution which was allowed to stir overnight. The particles were then concentrated up to 22 ml. AEABE (60 mg @100 mg/ml) was mixed with 60 mg NHS (100 mg/ml in DMF) and the NHS-ester formed by reaction with 35 60 mg DCC (Dicyclohexylcarbodiimide, 103 mg/ml in DMF). Following 10 minute activation 5 and 40 mg aliquots of the (NHS)2~AEABE were added to 11 ml aliquots of nanoparticles. The reaction was allowed to proceed overnight. The particles were then dialysed extensively against DW to remove free AEABE. Each sample was further split into 2. Adipyl-hydrazide-eVB12 (20 40 mg) plus 20 mg EDAC was added to one sample while TSTU-activated-eVB12 PCT/I B98/01464 (20 mg) was added to the other sample and allowed to react for 2 hours. The samples were then dialysed against distilled water and tested following oral administration to rats. As shown in Figure 5, all particle preparations resulted in a reduction in serum glucose for a period of 5 hours after oral administration.
As used herein, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or 10 group of elements or integers.

Claims (53)

What we claim is:
1. A cross-linked particle comprising at least one polymer capable of forming a particle, wherein said, polymer 5 comprises reactive carboxyl groups covalently cross-linked via a spacer selected from the group consisting of hydrazine and a group having the formula: NH2NHCO-R-CONHNH2, wherein -R- is a direct bond, or R is a straight, branched chain or cyclic alkyl, alkenyl, alkynyl or aryl ) group, wherein said alkyl, alkenyl, or alkynyl group contains up to 10 carbon atoms.
2. A cross-linked particle according to claim 1" wherein said spacer is selected from the group consisting of: oxalic dihydrazide, malonic dihydrazide, succinic dihydrazide, glutaric dihydrazide, adipic dihydrazide, maleic dihydrazide, fumaric dihydrazide or butadienoic dihydrazide, glutamic dihydrazide, aspartic dihydrazide, malic dihydrazide, tartaric dihydrazide, terephthalic dihydrazide, isophthalic dihydrazide, and phthalic dihy dr a z i de.
3. A cross-linked particle comprising at least one polymer capable of forming a particle, wherein said polymer comprises reactive amino, hydrazidyl, of"thiol groups, covalently linked to a spacer selected from . the group consisting of maloriic acid, maleic acid, malic acid, citric acid, glutamic acid, aspartic acid, succinic acid, adipic acid, glutaric acid, dimethyl'g.lutaric acid, oxalic acid, fumaric acid, phthalic .acid," tartaric acid, isophthalic acid, and terephthalic acid and the branched alkyl derivatives thereof, wherein the alkyl group of said alkyl derivatives contains up to 10 carbon atoms.
4. A cross-linked particle comprising at least one polymer capable of forming a particle, wherein said polymer comprises: (i) reactive groups selected from the group consisting of carboxyl, hydrazidyl, amino and thiol groups, covalently linked to (ii) a spacer comprising at least one reactive carboxyl group and at least one reactive hydrazidyl group. 27 k*aual property! office of n.z. i 1 o SEP 2003 I received
5. A cross-linked particle according to any of claims 1-4, wherein said spacer comprises at least one biodegradable linkage. 5
6. A cross-linked particle according to claim 5, wherein said biodegradable linkage is an ester linkage.
7. A cross-linked particle according Lo claim 6 wherein said spacer is a 2 aminoethyl ester of an amino 10 acid.
8. A cross-linked particle according to claim 7, wherein said spacer is selecCed f-rom the group consisting . of: the 2-aminoethyl esters of glycine and phenylalanine, 15 and the disuccinimidyl derivatives of th&. 2-axninoethyl esters of glycine and phenylalanine.
9. A cross-linked particle according to claim 8, wherein said disuccinimidyl derivatives "«f the 2-aminoethyl 20 esters of glycine and phenylalanine are selected from the group consisting of N,N'-disuccinimidyl-(2-amino-2-benzyl-ethanoate) , N, N' -dissuccinimidyl-2-amino-'ethyl-ethanoate, and ethylene glycolbis[succinimidylsuccinate] 25
10. A cross-linked particle according to any of claims 1-9, wherein said particle is covalently bound to a targeting.compound.
11. A composition comprising a pharmaceutical agent. 3 0 entrapped within a cross-linked particle according to any of claims 1-10.
12. A composition according to claim 11, wherein said pharmaceutical agent is selected from the group consisting 35 of peptide and protein pharmaceuticals, DNA, RNA, antibodies, vaccines, imaging agents, hormones, polysaccharides, antibiotics, anticoagulants, immunomodulating agents, cytotoxic agents, steroids, decongestants, anesthetics and sedatives. 40
13. A composition according to claim 12, wherein said pharmaceutical agent is selected from the group consisting of calcitonin, erythropoietin, thrombopoietin, granulocyte colony stimulating factor, stem cell factor, LHRH analogs-, 45 somatostatin, insulin, interferons and plasminogen activator inhibitors.
14. A method of producing a cross-linked particle 28 intellectual property office of N.z. 10 SEP 2003 received comprising cross-linking at least one polymer capable of forming a particle with a spacer., wherein said polymer comprises reactive carboxyl groups, 5 wherein said spacer is selected from the group consisting of hydrazine and a group having the formula NM2NHC°_K-CONHNH2/ wherein -R- is a direct bond, or R is a straight, branched chain or cyclic alkyl, alkenyl, alkynyl oj: aryl group, wherein said" alkyl, alkenyl,. or alkynyl 10 group contains up to 10 carbon atoms, and wherein said cross-linking is achieved using a carbodiimide as a cross-linking agent.
15. A method according to claim 14, wherein said 15 spacer is selected from the group consisting of: oxalic dihydrazide, malonic dihydrazide, succinic dihydrazide, glutaric dihydrazide, adipic dihydrazide, maleic di-hydrazide, fumaric dihydrazide or. butadienoic dihydrazide, glutamic dihydrazide, aspartic dihydrazide, 20 malic dihydrazide, tartaric dihydrazide, terephthalic dihydrazide, isophthalic dihydrazide, and phthalic dihydra z i de.
16. A method of producing a cross-linked particle 25 comprising cross-linking at least one polymer capable of forming a particle with a spacer, wherein said polymer comprises reactive' amino, hydrazidyl, or thiol groups, wherein said spacer is selected from the group 30 consisting of malonic acid, maleic acid, malic acid, citric acid, glutamic acid, aspartic acid., succinic acid, adipic acid, . glutaric acid, dimethylglutaric acid, oxalic acid, fumaric acid, phthalic acid, tartaric acid, isophthalic acid, and terephthalic acid and the branched alkyl 35 derivatives thereof, wherein the alkyl group of said alkyl derivatives contains up to 10 carbon atoms, and wherein said cross-linking is achieved using a carbodiimide as a cross-linking agent. 40
17. A method of producing a cross-linked particle comprising cross-linking at least one polymer capable of forming a particle with a spacer, wherein said polymer comprises reactive groups 45 selected from the group consisting of carboxyl, hydrazidyl, amino and thiol groups, and intellectual property office of n.z. 10 SEP 2003 received wherein said spacer comprises at least one reactive carboxyl group and at least one reactive hydrazidyl group, and wherein said cross-linking is achieved using a 5 carbodiimide as a cross-linking agent.
18. The method according to any of claims 14-17, wherein said carbodiimide is selected from the group consisting of N-ethyl-N'- (3-dimethylaminopropyl) - 10 carbodiimide, N,N' -dicyclohexyl-carbodiimide (DCC), N'- diisopropyl-carbodiimide, N'N'-di-tert-butylcarbodiimide 1-cyclohexyl-3-(4-diethylamino-cyclohexyl)carbodiimide, 1,3-di-(4-diethylaminocyclohexyl)carbodiimide, l-cyclohexyl-3-(-diethylaminoethyl) carbodiimide, l-cyclohexyl-3-(2-15 morpholinyl-(4)-ethyl)carbodiimide, and l-cyclohexyl-3-(4-diethyl-aminocyclohexyl) carbodiimide.
19. The method according to any of claims 14-18, wherein said spacer comprises at least one biodegradable 20 linkage.
20. A method of preparing a composition comprising a pharmaceutical agent entrapped within a cross-linked particle, comprising cross-linking at least ..one polymer 25 capable of forming a particle with a spacer in the presence of said pharmaceutical agent, wherein said polymer comprises reactive carboxyl groups, wherein said spacer is selected from the group 30 consisting of hydrazine and a group having the formula NH2NHCO-R-CONHNH2 f wherein -R- is a direct bond, or R is a straight, branched chain or cyclic alkyl, alkenyl, alkynyl or aryl group, wherein said alkyl, alkenyl, or alkynyl group contains up to 10 carbon atoms, and 35 wherein said cross-linking is achieved using a carbodiimide as a cross-linking agent.
21. A method according to claim 20, wherein said spacer is selected from the group consisting of: oxalic 40 dihydrazide, malonic dihydrazide, succinic dihydrazide, glutaric dihydrazide, adipic dihydrazide, maleic dihydrazide, fumaric dihydrazide or butadienoic dihydrazide, glutamic dihydrazide, aspartic dihydrazide, malic dihydrazide, tartaric dihydrazide, terephthalic 45 dihydrazide, isophthalic dihydrazide, and phthalic dihydrazide.
22. A method of preparing a composition comprising a pharmaceutical agent entrapped within a cross-linked H:\Emma\Keep\Specis\PCT-IB99-01464 RESPONSE.doc 13/09/99 •go particle, comprising cross-linking at least one polymer capable of forming a particle with a spacer in the presence of said pharmaceutical agent, wherein said polymer comprises reactive amino, 5 hydrazidyl, or thiol groups, wherein said spacer is selected from the group consisting of malonic acid, maleic acid, malic acid, citric acid, glutamic acid, aspartic acid, succinic acid, adipic acid, glutaric acid, dimethylglutaric acid, oxalic acid, 10 fumaric acid, phthalic acid, tartaric acid, isophthalic acid, and terephthalic acid and the branched alkyl derivatives thereof, wherein the alkyl group of said alkyl derivatives contains up to 10 carbon atoms, and wherein said cross-linking is achieved using a 15 carbodiimide as a cross-linking agent.
23 . A method of preparing a composition comprising a pharmaceutical agent entrapped within a cross-linked particle, comprising cross-linking at least one polymer 20 capable of forming a particle with a spacer in the presence of said pharmaceutical agent, wherein said polymer comprises reactive groups selected from the group consisting of carboxyl, hydrazidyl, amino and thiol groups, 25 wherein said spacer comprises at least one reactive carboxyl group and at least one reactive hydrazidyl group, wherein said cross-linking is achieved using a carbodiimide as a cross-linking agent. 30
24. The method according to any of claims 20-23, wherein said carbodiimide is selected from the group consisting of N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide, N,N'-dicyclohexyl-carbodiimide (DCC), N'-diisopropyl-carbodiimide, N'N'-di-tert-butylcarbodiimide 1-35 cyclohexyl-3-(4-diethylamino-cyclohexyl)carbodiimide, 1,3-di-(4-diethylaminocyclohexyl)carbodiimide, l-cyclohexyl-3-(S-diethylaminoethyl) carbodiimide, 1-cyclohexyl-3-(2-morpholinyl-(4)-ethyl)carbodiimide, and 1-cyclohexyl-3-(4-diethyl-aminocyclohexyl) carbodiimide. 40
25. The method according to any of claims 20-24, wherein said spacer comprises at least one biodegradable linkage. 45
26. The method according to any of claims 20-25, wherein said the pharmaceutical agent is selected from the group consisting of peptide and protein pharmaceuticals, DNA, RNA, antibodies, vaccines, imaging agents, hormones, polysaccharides, antibiotics, anticoagulants, H:\EaunaUCeep\Specxs\PCT-IB98-01464 RESPONSE.doc 1J/09/99 SI immunomodulating agents, cytotoxic agents, steroids, decongestants, anaesthetics and sedatives.
27. The method according to claim 26, wherein said 5 pharmaceutical agent is selected from the group consisting of calcitonin, erythropoietin, thrombopoietin, granulocyte colony stimulating factor, stem cell factor, LHRH analogs, somatostatin, insulin, interferons and plasminogen activator inhibitors. 10
28. Use of a composition comprising a pharmaceutical agent within a cross-linked particle for the manufacture of a medicament for achieving controlled release of a pharmaceutical agent within a patient, wherein said cross- 15 linked particle comprises at least one polymer capable of forming a particle, wherein said polymer comprises reactive carboxyl groups covalently cross-linked via a spacer selected from the group consisting of hydrazine and a group having the 20 formula: NH2NHCO-R-CONHNH2/ wherein -R- is a direct bond, or R is a straight, branched chain or cyclic alkyl, alkenyl, alkynyl or aryl group, wherein said alkyl, alkenyl, or alkynyl group contains up to 10 carbon atoms. 25
29. Use according to claim 28 wherein said spacer is selected from the group consisting of: oxalic dihydrazide, malonic dihydrazide, succinic dihydrazide, glutaric dihydrazide, adipic dihydrazide, maleic dihydrazide, fumaric 3 0 dihydrazide or butadienoic dihydrazide, glutamic dihydrazide, aspartic dihydrazide, malic dihydrazide, tartaric dihydrazide, terephthalic dihydrazide, isophthalic dihyrazide, and phthalic dihydrazide.
^ 30. Use of a composition comprising a pharmaceutical agent within a cross-linked particle for the manufacture of a medicament for achieving controlled release of a pharmaceutical agent within a patient, wherein said cross-linked particle comprises at least one polymer capable of forming a particle, wherein said polymer comprises reactive amino, hydrazidyl, or thiol groups, covalently linked to a spacer selected from the group consisting of malonic acid, maleic ^5 acid, malic acid, citric acid, glutamic acid, aspartic acid, succinic acid, adipic acid, glutaric acid, dirnethylglutaric acid, oxalic acid, fumaric acid, phthalic 32 intellectual property office of n.z. 10 SEP 2003 received acid, tartaric acid, isophthalic acid, and terephthalic acid and the branched alkyl derivatives thereof, wherein the alkyl group of said alkyl derivatives contains up to 10 carbon atoms.
31. Use of a composition comprising a pharmaceutical agent within a cross-linked particle for the manufacture of a medicament for achieving controlled release of a pharmaceutical agent within a patient, wherein said cross-linked particle comprises at least one polymer capable of forming a particle, wherein said polymer comprises: (i) reactive groups selected from the group consisting of carboxyl, hydrazidyl, amino and thiol groups, covalently linked to (ii) a spacer comprising at least one reactive carboxyl group and at least one reactive hydrazidyl group.
32. Use according to any of claims 28-31, wherein said spacer comprises at least one biodegradable linkage.
33. Use according to claim 32, wherein said biodegradable linkage is an ester linkage.
34. Use according to claim 33 wherein said spacer is a 2 aminoethyl ester of an amino acid.
35. Use according to claim 34, wherein said spacer is selected from the group consisting of: the 2-aminoethyl esters of glycine and phenylalanine, and the disuccinimidyl derivatives of the 2-aminoethyl esters of glycine and phenylalanine.
36. Use according ! to claim 35, wherein said disuccinimidyl derivatives of the 2-aminoethyl esters of glycine and phenylalanine are selected from the group consisting of N,N'-disuccinimidyl- (2-amino-2-benzyl-ethanoate), N,N'-dissuccinimidyl-2-amino-ethyl-ethanoate, and ethylene glycolbis [succinimidylsuccinate].
37. Use according to any of claims 28-36, wherein said particle is covalently bound to a targeting compound.
38. Use according to any of claims 28-37, wherein said pharmaceutical agent is selected from the group consisting of peptide and protein pharmaceuticals, intellectual property office of n.z. 10 SEP 2003 received DNA, RNA, antibodies, vaccines, imaging agents, hormones, polysaccharides, antibiotics, anticoagulants, immunomodulating agents, cytotoxic agents, steroids, decongestants, anesthetics and sedatives. 5
39. Use according to claim 38, wherein said pharmaceutical agent is selected from the group consisting of calcitonin, erythropoietin, thrombopoietin, granulocyte colony stimulating factor, stem cell factor, LHRH analogs, 10 somatostatin, insulin, interferons and plasminogen activator inhibitors.
40. A composition for delivering a pharmaceutical agent, comprising a cross -^linked particle and a 15 pharmaceutical agent entrapped within said cross—linked particle, wherein said particle comprises a polycationic polymer cross-linked to a polyanionic polymer via a spacer moiety, wherein said spacer moiety comprises at least two 20 reactive groups selected from the group consisting of carboxyl, hydrazidyl, amino and thiol groups.
41. A composition according to claim 40, wherein said spacer is selected from the group consisting of hydrazine 25 and a group having the formula: NH2NHCO-R-^CONHNH2 wherein -R- is a direct bond, or R is a straight, branched chain or cyclic alkyl, alkenyl, alkynyl or aryl group, wherein said alkyl, alkenyl, or alkynyl group contains up to 10 carbon atoms. 30
42. A composition according to claim 40 wherein said spacer is selected from the group consisting of: oxalic dihydrazide, malonic dihydrazide, succinic dihydrazide, glutaric dihydrazide, adipic dihydrazide, maleic 5 dihydrazide, fumaric dihydrazide or butadienoic dihydrazide, glutamic dihydrazide, aspartic dihydrazide, malic dihydrazide, tartaric dihydrazide, terephthalic . dihydrazide, isophthalic dihydrazide, and phthalic dihydrazide. D
43 . ■ A composition according to claim 40, wherein said spacer is selected from the group consisting of malonic acid, maleic acid, malic acid, citric acid, glutamic acid, aspartic acid, succinic acid, adipic acid, glutaric acid, i dimethylglutaric. acid, oxalic acid, fumaric acid, phthalic acid, tartaric acid, isophthalic acid, and terephthalic acid and the branched alkyl derivatives thereof, wherein the alkyl group of said alkyl derivatives contains up to 10 carbon atoms. intellectual property office of n.z. t 0 SEP 2003 receive!) 5 1 78 0 2
44. A composition according to claim 40, wherein said spacer comprises at least one reactive carboxyl group and at least one reactive hydrazidyl group.
45. A composition according to any of claims 40-44, wherein said spacer comprises at least one biodegradable linkage.
46. A composition according to claim 45, wherein said biodegradable linkage is an ester linkage.
47. A composition according to claim 46 wherein said spacer is a 2 aminoethyl ester of an amino acid.
48. A composition according to claim 47, wherein said spacer is selected from the group consisting of: the 2-aminoethyl esters of glycine and phenylalanine, and the disuccinimidyl derivatives of the 2-aminoethyl esters of glycine and phenylalanine.
49. A composition according to claim 48, wherein said disuccinimidyl derivatives of the 2-aminoethyl esters of glycine and phenylalanine are selected from the group consisting of N,N'-disuccinimidyl-(2-amino-2-benzyl-ethanoate) , N,N'-dissuccinimidyl-2-amino-ethyl-ethanoate, and ethylene glycolbis[succinimidylsuccinate]
50. A composition according to any of claims 40-49, wherein said particle is covalently bound to a targeting compound.
51. A cross-linked particle suitable for delivering a pharmaceutical composition, comprising at least one polymer capable of forming a particle, wherein said polymer is cross linked to a spacer via a reactive cyanoacrylate moiety.
52. A particle according to claim 51, wherein said spacer is 2-aminoethyl-2-amino-2-benzyl-ethanoate.
53. A particle according to claim 51 or 52, wherein said cyanoacrylate is isobutylcyanoacrylate. DATED this 12th day of March 2002 BIOTECH AUSTRALIA PTY LTD intellectual property office of n.z. By its Patent Attorneys 1 4 MAR 2002 received H:\Emmii\Keep\Specis\PCT-IB98-01464 RESPONSE .doc 13/09/99
NZ517802A 1997-08-29 2002-03-14 Surface cross-linked particles suitable for controlled delivery in pharmaceutical use NZ517802A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPO8880A AUPO888097A0 (en) 1997-08-29 1997-08-29 Cross-linked particles
NZ50357902 2002-03-14

Publications (1)

Publication Number Publication Date
NZ517802A true NZ517802A (en) 2003-10-31

Family

ID=29251534

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ517802A NZ517802A (en) 1997-08-29 2002-03-14 Surface cross-linked particles suitable for controlled delivery in pharmaceutical use

Country Status (1)

Country Link
NZ (1) NZ517802A (en)

Similar Documents

Publication Publication Date Title
US6221397B1 (en) Surface cross-linked particles suitable for controlled delivery
CA2084194C (en) Oral delivery systems for microparticles
JP5211109B2 (en) Composite of transmembrane agent and pharmaceutically active ingredient
US20110301097A1 (en) Oral Administration Of Therapeutic Agent Coupled To Transporting Agent
JP2002543110A (en) Amplification of folate-mediated targeting to tumor cells using nanoparticles
GB2374010A (en) Novel vitamin B12 - biodegradable micro particulate conjugate carrier systems for peroral delivery of drugs, therapeutic peptides/proteins and vaccines
CN101489574A (en) Physiologically active polypeptide or protein-encapsulating polymer micelle and method for producing same
Arias et al. Elastin-like recombinamers as smart drug delivery systems
Vaidya et al. Bioconjugation of polymers: a novel platform for targeted drug delivery
AU723807B2 (en) Cross-linked particles
NZ517802A (en) Surface cross-linked particles suitable for controlled delivery in pharmaceutical use
KR101210713B1 (en) Temperature-sensitive bioactive agent delivery system and method for producing it
Yang et al. Design Principles, Synthetic Strategies, and Biomedical Applications of Peptide–Polymer Conjugates
CZ2000731A3 (en) Cross-linked particles suitable for application of pharmaceutical preparation, process of their preparation, pharmaceutical preparation in which they are comprised and process of their preparation
JPH09124512A (en) Water-soluble medicine-pullulan combination preparation for targeting liver
AU707085B2 (en) Oral delivery systems for microparticles
Steiert Dynamic Protein-based Nanoparticles for Drug Delivery Applications
US20050208032A1 (en) Oral administration of therapeutic agent coupled to transporting agent
Arias Vallejo et al. Elastin-like recombinamers as smart drug delivery systems
WO2006077456A1 (en) Oral administration of therapeutic agent coupled to transporting agent
HK1002252B (en) Oral delivery systems for microparticles
AU2004201276A1 (en) Amplification of folate-mediated targeting to tumor cells using nanoparticles

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: ACCESS PHARMACEUTICALS AUSTRALIA PTY LIMITED, AU

Free format text: OLD OWNER(S): BIOTECH AUSTRALIA